A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma

Part of paid clinical trials in Basking Ridge, New Jersey.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT05788289
Phase
PHASE2
Status
Terminated

Conditions

  • MCL
  • Mantle Cell Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tafasitamab — DRUG
    Participants will receive treatment with intravenous tafasitamab and oral lenalidomide for up to 12 cycles. Each cycle is 28 days in length.
  • Lenalidomide — DRUG
    Lenalidomide will be self-administered by patients orally on days 1-21 of each 28-day cycle of induction (cycles 1 through 12).

Study Details

The purpose of this study is to determine if the combination of tafasitamab and lenalidomide is an effective treatment for relapsed or refractory Mantle Cell Lymphoma.

Key Dates

Start date
Mar 14, 2023
Status verified
May 2025
Primary completion
Aug 1, 2024
Completion
Aug 1, 2024

Study Design

Enrollment
4 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Participants with Mantle Cell Lymphoma
    Participants have a diagnosis of Mantle Cell Lymphoma have previously failed or could not tolerate Bruton's tyrosine kinase inhibitors/BTKi

Primary Outcome Measure

Overall Response Rate/ORR [ Time Frame: completion of 12 cycles of treatment (each cycle is 28 days) or at treatment discontinuation, whichever comes first ]

Locations (7)

Find similar trials in Basking Ridge, NJ

Related Studies